Gonadotropin-releasing hormone analogs and prostatic cancer.
Analogs of GnRH constitute a new category of drugs available for the treatment of advanced prostatic cancer. The efficacy and safety of GnRH analogs in the treatment of this disease is now well established. These compounds represent an important alternative therapy for advanced prostatic cancer patients who do not wish to undergo orchiectomy or for whom DES is not tolerable because of the risk of cardiovascular complications. The advent of the monthly depot form of these drugs will make treatment more convenient and less invasive and will enhance patient compliance.
Swanson
L J
LJ
Abbott Laboratories, Abbott Park, Illinois.
Seely
J H
JH
Garnick
M B
MB
D000726:Androgen Antagonists / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002064:Buserelin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D016729:Leuprolide; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D017329:Triptorelin Pamoate
D000726:Androgen Antagonists; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide; D002064:Buserelin